Baird raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $162 from $154 and keeps an Outperform rating on the shares. The firm views the uptick of patients on Xywav during 3Q24 as particularly reassuring for that agent’s outlook over the coming quarters. They view the key upcoming catalyst for the stock as phase 3 topline PFS results on zanidatamab in first-line gastroesophageal adenocarcinoma (GEA) in 2Q25.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Biotech Alert: Searches spiking for these stocks today
- Jazz Pharmaceuticals price target lowered to $195 from $200 at TD Cowen
- Jazz Pharmaceuticals price target raised to $182 from $172 at BofA
- Jazz Pharmaceuticals price target lowered to $190 from $200 at Barclays
- Zymeworks upgraded to Outperform from Market Perform at Leerink